Vandyke K - Search Results

1

SAMSN1 is a tumor suppressor gene in multiple myeloma.

Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. Noll JE, et al. Among authors: vandyke k. Neoplasia. 2014 Jul;16(7):572-85. doi: 10.1016/j.neo.2014.07.002. Neoplasia. 2014. PMID: 25117979 Free PMC article.

2

Imatinib mesylate causes growth plate closure in vivo.

Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino AC. Vandyke K, et al. Leukemia. 2009 Nov;23(11):2155-9. doi: 10.1038/leu.2009.150. Epub 2009 Jul 23. Leukemia. 2009. PMID: 19626049 No abstract available.

3

Dysregulation of bone remodeling by imatinib mesylate.

Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Vandyke K, et al. Blood. 2010 Jan 28;115(4):766-74. doi: 10.1182/blood-2009-08-237404. Epub 2009 Nov 4. Blood. 2010. PMID: 19890095 Free article. Review.

4

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.

Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC. Vandyke K, et al. J Bone Miner Res. 2010 Aug;25(8):1759-70. doi: 10.1002/jbmr.85. J Bone Miner Res. 2010. PMID: 20225261 Free article.

5

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Fitter S, et al. Among authors: vandyke k. J Clin Endocrinol Metab. 2010 Aug;95(8):3763-7. doi: 10.1210/jc.2010-0086. Epub 2010 May 13. J Clin Endocrinol Metab. 2010. PMID: 20466781 Clinical Trial.

6

Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.

Fitter S, Vandyke K, Gronthos S, Zannettino AC. Fitter S, et al. Among authors: vandyke k. J Mol Endocrinol. 2012 May 8;48(3):229-40. doi: 10.1530/JME-12-0003. Print 2012 Jun. J Mol Endocrinol. 2012. PMID: 22474082

7

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation.

Vandyke K, Fitter S, Zannettino AC. Vandyke K, et al. Blood Cancer J. 2011 Feb;1(2):e2. doi: 10.1038/bcj.2011.1. Epub 2011 Feb 4. Blood Cancer J. 2011. PMID: 22829108 Free PMC article. No abstract available.

8

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC. Vandyke K, et al. J Clin Endocrinol Metab. 2013 Jan;98(1):67-76. doi: 10.1210/jc.2012-2426. Epub 2012 Nov 8. J Clin Endocrinol Metab. 2013. PMID: 23144472 Clinical Trial.

9

EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.

Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, Vandyke K, Zannettino AC, Koblar SA, Sims NA, Matsuo K, Gronthos S. Arthur A, et al. Among authors: vandyke k. J Bone Miner Res. 2013 Apr;28(4):926-35. doi: 10.1002/jbmr.1821. J Bone Miner Res. 2013. PMID: 23165754 Free article.

10

Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.

Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC. Vandyke K, et al. Br J Haematol. 2013 May;161(4):499-507. doi: 10.1111/bjh.12280. Epub 2013 Feb 26. Br J Haematol. 2013. PMID: 23438504 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page